VIM and breast cancer: The Vimentin/POU4F2 combined methylation panel achieved an AUC of 0.935 (95% CI: 0.889–0.981), with sensitivity, specificity, and accuracy of 86.44% (95% CI: 0.772–0.957), 96.08% (95% CI: 0.923–0.998), and 92.55% (95% CI: 0.886–0.965) for diagnosing BC.